SCHEMBL215860

SCHEMBL215860

Cc1ccc(Br)cc1-n1cnc(C(N)=O)c1C(=O)Nc1ccc(F)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
RXFP1 Q9HBX9 1/20 0.38
ALDH1A1 P00352 3/20 0.38
MAPT P10636 3/20 0.38
NPC1 O15118 4/20 0.37
RAB9A P51151 4/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
IDO1 P14902 2/20 0.37
GAA P10253 1/20 0.37
PTGFR P43088 1/20 0.37
ABL1 P00519 1/20 0.36
BCR P11274 1/20 0.36
LMNA P02545 1/20 0.36
ALOX15 P16050 1/20 0.36
POLB P06746 1/20 0.36
CXCR2 P25025 1/20 0.36
SORT1 Q99523 1/20 0.36
RIPK1 Q13546 1/20 0.36
SCN9A Q15858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL213975 0.92 KMT2A (0.42) MEN1KMT2ARXFP1ALDH1A1MAPT
SCHEMBL214245 0.90 NPC1 (0.41) MEN1KMT2AALDH1A1MAPTNPC1
SCHEMBL215228 0.90 SCN9A (0.44) MEN1KMT2ARXFP1ALDH1A1MAPT
SCHEMBL215824 0.90 RAB9A (0.41) MEN1KMT2ARXFP1ALDH1A1MAPT
SCHEMBL214745 0.88 KMT2A (0.41) MEN1KMT2ARXFP1ALDH1A1MAPT
SCHEMBL214707 0.87 GAA (0.47) KMT2ARXFP1ALDH1A1MAPTNPC1
SCHEMBL214574 0.86 RAB9A (0.41) MEN1KMT2ARXFP1ALDH1A1MAPT
SCHEMBL213700 0.85 SORT1 (0.46) MEN1KMT2ARXFP1ALDH1A1MAPT
SCHEMBL215330 0.83 ALDH1A1 (0.46) MEN1KMT2AALDH1A1MAPTNPC1
SCHEMBL214029 0.82 MAPT (0.46) MEN1KMT2AALDH1A1MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed
EP-2061768-A2 IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS Exelixis, Inc. (US) 2009-05-27 EP disclosed
WO-2008042282-A2 IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS EXELIXIS, INC. (US) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 MEN1 3504/4885KMT2A 437/4885RXFP1 4143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.